Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Proc Natl Acad Sci U S A
2001 Sep 25;9820:11545-50. doi: 10.1073/pnas.191112198.
Show Gene links
Show Anatomy links
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen.
Wei YQ
,
Huang MJ
,
Yang L
,
Zhao X
,
Tian L
,
Lu Y
,
Shu JM
,
Lu CJ
,
Niu T
,
Kang B
,
Mao YQ
,
Liu F
,
Wen YJ
,
Lei S
,
Luo F
,
Zhou LQ
,
Peng F
,
Jiang Y
,
Liu JY
,
Zhou H
,
Wang QR
,
He QM
,
Xiao F
,
Lou YY
,
Xie XJ
,
Li Q
,
Wu Y
,
Ding ZY
,
Hu B
,
Hu M
,
Zhang W
.
???displayArticle.abstract???
Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic homologous gene, targeting the growth factors associated with angiogenesis. To test this concept, we constructed a plasmid DNA encoding Xenopus homologous VEGF (XVEGF-p) and control vectors. We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice. VEGF-specific autoantibodies in sera of mice immunized with XVEGF-p could be found in Western blotting analysis and ELISA assay. The purified immunoglobulins were effective at the inhibition of VEGF-mediated endothelial cell proliferation in vitro, and at antitumor activity and the inhibition of angiogenesis by adoptive transfer in vivo. The elevation of VEGF in the sera of the tumor-bearing mice could be abrogated with XVEGF-p immunization. The antitumor activity and production of VEGF-specific autoantibodies, significantly elevated IgG1 and IgG2b, could be abrogated by the depletion of CD4(+) T lymphocytes. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factors associated with tumor growth in a cross reaction with single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.
Amagai,
Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
1998, Pubmed
Amagai,
Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.
1998,
Pubmed
Arap,
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
1998,
Pubmed
Blezinger,
Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene.
1999,
Pubmed
Boon,
Tumor antigens recognized by T cells.
1997,
Pubmed
Bowne,
Coupling and uncoupling of tumor immunity and autoimmunity.
1999,
Pubmed
Breier,
Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.
1992,
Pubmed
Carmeliet,
Angiogenesis in cancer and other diseases.
2000,
Pubmed
Cleaver,
Neovascularization of the Xenopus embryo.
1997,
Pubmed
,
Xenbase
Corr,
Gene vaccination with naked plasmid DNA: mechanism of CTL priming.
1996,
Pubmed
De Luca,
Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts.
2000,
Pubmed
De Silva,
CD4+ T cells, but not CD8+ T cells, are required for the development of experimental autoimmune gastritis.
1998,
Pubmed
Fan,
Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy.
1995,
Pubmed
Ferrara,
Clinical applications of angiogenic growth factors and their inhibitors.
1999,
Pubmed
Fidler,
The implications of angiogenesis for the biology and therapy of cancer metastasis.
1994,
Pubmed
Folkman,
What is the evidence that tumors are angiogenesis dependent?
1990,
Pubmed
Folkman,
What is the role of thymidine phosphorylase in tumor angiogenesis.
1996,
Pubmed
Horton,
A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.
1999,
Pubmed
Houghton,
Immunity against cancer: lessons learned from melanoma.
2001,
Pubmed
Kerbel,
A cancer therapy resistant to resistance.
1997,
Pubmed
Keyt,
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.
1996,
Pubmed
Kim,
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
1993,
Pubmed
Kornberg,
The Drosophila genome sequence: implications for biology and medicine.
2000,
Pubmed
Krieg,
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.
1998,
Pubmed
Kumar,
Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE).
1996,
Pubmed
Leung,
Vascular endothelial growth factor is a secreted angiogenic mitogen.
1989,
Pubmed
Mosmann,
The expanding universe of T-cell subsets: Th1, Th2 and more.
1996,
Pubmed
O-Charoenrat,
Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells.
2000,
Pubmed
Ohashi,
T cell selection and autoimmunity: flexibility and tuning.
1996,
Pubmed
Overwijk,
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
1999,
Pubmed
Pardoll,
Inducing autoimmune disease to treat cancer.
1999,
Pubmed
Pulendran,
Distinct dendritic cell subsets differentially regulate the class of immune response in vivo.
1999,
Pubmed
Rinaldi,
Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
2001,
Pubmed
Risau,
Mechanisms of angiogenesis.
1997,
Pubmed
Romagnani,
The Th1/Th2 paradigm.
1997,
Pubmed
Rosenberg,
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
1997,
Pubmed
Roth,
Gene therapy for cancer: what have we done and where are we going?
1997,
Pubmed
Sauter,
Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases.
2000,
Pubmed
Schwartz,
T cell clonal anergy.
1997,
Pubmed
Sedgwick,
A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.
1983,
Pubmed
Stacker,
A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.
1999,
Pubmed
Treon,
Interleukin-6 in multiple myeloma and related plasma cell dyscrasias.
1998,
Pubmed
Volpert,
A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.
1998,
Pubmed
Weber,
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
1998,
Pubmed
Wei,
Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine.
2000,
Pubmed
Wei,
Induction of apoptosis by quercetin: involvement of heat shock protein.
1994,
Pubmed
Wei,
Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70.
1996,
Pubmed
Yancopoulos,
Vascular-specific growth factors and blood vessel formation.
2000,
Pubmed
Zetter,
Angiogenesis and tumor metastasis.
1998,
Pubmed